Form 8-K - Current report:
SEC Accession No. 0001999371-25-007790
Filing Date
2025-06-16
Accepted
2025-06-16 07:32:15
Documents
15
Period of Report
2025-06-16
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_06162025.htm   iXBRL 8-K 31164
2 PRESS RELEASE ex99-01.htm EX-99.01 34955
3 ADVANCING FIBROMYALGIA TREATMENT ex99-02.htm EX-99.02 1427
4 GRAPHIC tnxp-ex9902.jpg GRAPHIC 1550399
  Complete submission text file 0001999371-25-007790.txt   2379458

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tnxp-20250616.xsd EX-101.SCH 2990
6 XBRL LABEL FILE tnxp-20250616_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE tnxp-20250616_pre.xml EX-101.PRE 22342
17 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_06162025_htm.xml XML 3551
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 251048536
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)